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e ANSES, Agence Nationale de Sécurité Sanitaire de l’alimentation, de l’environnement et du travail, Direction de l’Evaluation des Risques, Unité Evaluation des 
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A B S T R A C T   
Background and aim: Endocrine disrupting chemicals (EDCs) constitute a major public health concern because 
they can induce a large spectrum of adverse effects by interfering with the hormonal system. Rapid identification 
of potential EDCs using in vitro screenings is therefore critical, particularly for chemicals of emerging concerns 
such as replacement flame retardants (FRs). The review aimed at identifying (1) data gaps and research needs 
regarding endocrine disrupting (ED) properties of replacement FRs and (2) potential EDCs among these emerging 
chemicals. 
Methods: A systematic search was performed from open literature and ToxCast/Tox21 programs, and results from 
in vitro tests on the activities of 52 replacement FRs towards five hormone nuclear receptors (NRs) associated 
with reproductive outcomes (estrogen, androgen, glucocorticoid, progesterone, and aryl hydrocarbon receptors) 
were compiled and organized into tables. Findings were complemented with information from structure-based in 
silico model predictions and in vivo information when relevant. 
Results: For the majority of the 52 replacement FRs, experimental in vitro data on activities towards these five NRs 
were either incomplete (15 FRs) or not found (24 FRs). Within the replacement FRs for which effect data were 
found, some appeared as candidate EDCs, such as triphenyl phosphate (TPhP) and tris(1,3-dichloropropyl) 
phosphate (TDCIPP). The search also revealed shared ED profiles. For example, anti-androgenic activity was 
reported for 19 FRs and predicted for another 21 FRs. 
Discussion: This comprehensive review points to critical gaps in knowledge on ED potential for many replacement 
FRs, including chemicals to which the general population is likely exposed. Although this review does not cover 
all possible characteristics of ED, it allowed the identification of potential EDCs associated with reproductive 
outcomes, calling for deeper evaluation and possibly future regulation of these chemicals. By identifying shared 
ED profiles, this work also raises concerns for mixture effects since the population is co-exposed to several FRs 
and other chemicals.   
Abbreviations: ED, endocrine disrupting; EDCs, endocrine disrupting chemicals; NRs, nuclear receptors; FRs, flame retardants; EU, European Union; ER, estrogen 
receptor; AR, androgen receptor; GR, glucocorticoid receptor; PR, progesterone receptor; AhR, aryl hydrocarbon receptor; CAS, Chemical Abstracts Service; CoM-
PARA, Collaborative Modeling Project for Androgen Receptor Activity; DR, dose-response; AC50, EC50 and IC50, 50% activity (AC50), effective (EC50) or inhibitory 
(IC50) concentration; REC20 and RIC20, 20% relative effective (REC20) or inhibitory (RIC20) concentration; PBDEs, polybrominated diphenyl ethers; QSAR, 
quantitative structure-activity relationship. 
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1. Introduction 
The endocrine system regulates key interrelated functions in the 
body, including reproduction, early development, as well as metabolic 
and neurologic processes. In the past decades, many chemicals used in 
manufactured products and agriculture, for example, have accumulated 
in food, water, and indoor environments, interfering with the endocrine 
system of both humans and wildlife. Such exogenous chemicals or 
chemical mixtures that can cause adverse health effects by perturbing 
any aspect of hormone action are defined as endocrine disrupting 
chemicals (EDCs) (Thomas Zoeller et al., 2012; WHO and UNEP, 2012). 
The United Nations Environment Programme (UNEP) established a 
conservative list of 45 EDCs or potential EDCs by reviewing evidence 
from multiple sources (United Nations Environment Programme, 2017). 
Nevertheless, the list is likely incomplete since many more chemicals 
have shown endocrine disrupting (ED) activities in humans and exper-
imental animals. Currently, more and more studies report associations 
between human exposure to EDCs and adverse outcomes, including 
male reproductive health (Sharma et al., 2020), metabolic disease 
(Heindel et al., 2017), and neurodevelopment (Mustieles and Fernández, 
2020). The potential impact of EDCs on public health is therefore of very 
high concern, and increasing efforts are being made in toxicological 
studies to test for ED properties of compounds that are newly introduced 
in the market. Currently, toxicity testing is shifting towards the use of 
alternative approaches to animal studies such as in vitro assays and in 
silico based modeling, following the 3Rs (Replacement, Reduction, and 
Refinement) recommendation of the Article 4 and 13 of the Directive 
2010/63/EU on the protection of animals used for scientific purposes 
(EU, 2011; Krewski et al., 2020). As part of this global movement to-
wards “non-animal” toxicology, the United States Environmental Pro-
tection Agency (US EPA) launched the Toxicity Forecaster (ToxCast) and 
Toxicity Testing in the 21st Century (Tox21) programs that use high- 
throughput screening methods to test a large number of chemicals 
over a large spectrum of in vitro assays, including several reporter assays 
for ED-related activities (https://www.epa.gov/chemical-research 
/toxicity-forecasting; https://comptox.epa.gov/dashboard/) (Judson 
et al., 2010). For EDCs, the in vitro screening often relies on assays 
testing for chemical affinity and action through hormonal nuclear re-
ceptors (NRs), which are usually classified into two major categories: 
steroid hormone receptors and heterodimers of retinoid X receptor (Hall 
and Greco, 2019; Toporova and Balaguer, 2020). EDCs may act on NRs 
either by mimicking the endogenous hormone and activating the re-
ceptor (agonists), or by inhibiting the effect of the hormone (antago-
nists) (Hall and Greco, 2019; Toporova and Balaguer, 2020). 
Information from these in vitro tests is particularly important for 
chemicals of emerging concern to which people are potentially exposed 
but for which toxicological data is scarce, if not absent. 
Replacement flame retardants (FRs) are a good example of such 
chemicals of emerging concern. Flame retardants are added to many 
consumer products used in our daily life, such as electronics, building 
insulators, textiles, furniture, to delay their eventual ignition. FRs, 
particularly those that are not chemically bound to the product matrix, 
tend to be emitted from the products and are broadly detected in indoor 
environments (air, dust), as well as in human matrices, suggesting that 
people may be chronically exposed to these chemicals (Mitro et al., 
2016; Rantakokko et al., 2019; Saillenfait et al., 2018). Due to their high 
environmental persistence and toxicity, the long-used polybrominated 
diphenyl ethers (PBDEs) and hexabromocyclododecane have been 
added to the Stockholm Convention on Persistent Organic Pollutants, 
and their use has been restricted (http://www.pops.int/TheConvent 
ion/ThePOPs/AllPOPs/tabid/2509/Default.aspx) (Sharkey et al., 
2020). Since then, the use of replacement FRs has markedly increased to 
assure compliance with flammability standards. The spectrum of 
chemicals has also enlarged, with hundreds of FRs now in the market 
showing quite diverse chemical structures. Organic FRs used as re-
placements include brominated (BFRs), organophosphate (OPFRs), and 
chlorinated (some of which are also OPFRs) flame retardants. As a result 
of their use, the replacement FRs are now detected in indoor air and 
dust, in the environment, biota, the food chain, as well as in human 
samples (Blum et al., 2019; Bollmann et al., 2012; Brandsma et al., 2015; 
Covaci et al., 2011; Demirtepe et al., 2019; Gbadamosi et al., 2021; 
Malarvannan et al., 2015; Mitro et al., 2016; Poma et al., 2017; Sail-
lenfait et al., 2018; Sundkvist et al., 2010; van der Veen and de Boer, 
2012; Vykoukalová et al., 2017; Wei et al., 2015; Zeng et al., 2014; 
Zuiderveen et al., 2020). Due to their ubiquity and ED potential, 
replacement FRs are among the priority compounds in the European 
Union (EU) assessed within the Human Biomonitoring for Europe 
(HBM4EU) initiative (HBM4EU - science and policy for a healthy 
future). Despite the clear evidence of increasing population exposure 
(Bastiaensen et al., 2020; Hoffman et al., 2017a), there is little or no 
information regarding the effects on human health for many replace-
ment FRs, but the few studies available suggest that some of them can 
induce adverse outcomes (Bajard et al., 2019; Blum et al., 2019). Besides 
possible neurodevelopmental or metabolic disruptions, several studies 
indicate that some replacement FRs may have ED properties related to 
reproductive outcomes (Hales and Robaire, 2020). Compounds like tris- 
2-chloroethyl phosphate (TCEP), tris(1,3-dichloropropyl)phosphate 
(TDCIPP), triphenyl phosphate (TPhP), tetrabromobisphenol A 
(TBBPA), or tricresyl phosphate (TMPP) were suggested to have adverse 
effects on the male reproductive tract and/or semen quality in rodents 
(Chen et al., 2015; EU RAR, 2009; European Union, 2008; US-EPA, 
2015; Zatecka et al., 2014, 2013). Small human cohort studies have 
also reported correlations between exposure to TPhP or TDCIPP and 
decreased sperm quality in humans (Carignan et al., 2018; Meeker et al., 
2013; Meeker and Stapleton, 2010). Consistently, the effects of 
replacement FRs on steroid hormone levels have been observed in ro-
dents and zebrafish (Chen et al., 2015; Liu et al., 2016, 2013, 2012; 
Pollock et al., 2017), and some in vitro studies reported estrogenic or 
anti-androgenic activities (Beck et al., 2016; Kojima et al., 2013; Kri-
voshiev et al., 2016; Reers et al., 2016; Rosenmai et al., 2021; Suzuki 
et al., 2013; Zhang et al., 2014). 
In this paper, a systematic search of the data available regarding the 
effects of replacement FRs on several NRs was performed, primarily 
focusing on steroid receptors, i.e., estrogen receptor (ER), androgen 
receptor (AR), glucocorticoid receptor (GR), and progesterone receptor 
(PR), which are associated to reproductive outcomes. Besides, the effects 
on the Aryl hydrocarbon receptor (AhR), which has been shown to cross- 
talk with steroid receptors such as ERs and AR, were also investigated 
(Ohtake et al., 2008). The search was done for 52 synthetic organic 
replacement FRs preselected by a group of experts of the HBM4EU 
initiative based on their hazardous properties, exposure, societal 
concern, and technical feasibility (Bajard et al., 2019) The list of 
chemicals with full names, abbreviations and CAS numbers is provided 
in Table S3, and the HBM4EU scoping document can be accessed 
through the following link: HBM4EU_D4.9_Scoping_Documents_HBM 
4EU_priority_substances_v1.0-Flame-retardants.pdf. 
2. Methods 
2.1. The overall procedure for collecting data 
The procedure is presented in Fig. 1. In brief, for each of the 52 
preselected replacement FRs, results from in vitro studies in which 
agonist or antagonist activities towards ER, AR, GR, PR, or AhR have 
been tested were collected from both the academic literature and Tox-
Cast database. The data collected was organized into tables, indicating 
whether the chemicals were tested, and, if so, in what assay(s) it was 
reported to be active or inactive, and what were the effective concen-
trations. As anti-androgenic activity appeared to be especially relevant 
(see results below), prediction of anti-androgenic activity from in silico 
models was also collected. The detailed procedures for data collection 
from the academic literature, ToxCast, and in silico model predictions are 
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explained in the following paragraphs. 
2.2. Academic peer-review literature search of in vitro data 
PubMed and Google Scholar were used to identify publications for 
each of the 52 preselected replacement FRs, using the following terms: 
(abbreviation OR full name of the chemical OR CAS number) AND 
((((endocrine) OR (nuclear receptors) OR (androgen) OR (estrogen) OR 
(glucocorticoid receptor) OR (progesterone receptor)))). For each rele-
vant paper (i.e., that contained tests for ER, AR, PR, GR or AhR agonist 
or antagonist activities), the name and type of the assay, whether the 
chemical was reported as active (A) or inactive (IN), and the effective 
concentration (for each assay in which the chemical was active) were 
recorded. Effective concentrations are the concentrations (in µM) at 
which 50% or 20% of the maximum response is achieved. They are 
expressed as the 50% activity (AC50), effective (EC50) or inhibitory 
(IC50) concentration, or the 20% relative effective (REC20) or inhibi-
tory (RIC20) concentration. A given chemical was considered as inactive 
if reported as such in the paper (e.g., not determined (ND), not effective 
(NE), not calculated (NC), etc.). Because criteria differ among studies 
and research papers, the highest concentration tested above which the 
chemical was considered to be inactive is indicated in Table S1. 
2.3. ToxCast search of in vitro data 
Results available in the ToxCast program were collected from the 
open dashboard of the US-EPA (https://comptox.epa.gov/dashboard), 
searching chemical by chemical using CAS numbers. Out of the 52 
preselected replacement FRs, 21 had been tested in ToxCast for ER, AR, 
GR, PR, or AhR activities. The list of ToxCast assays, with the name of 
the assay, the number of active chemicals, the total number of tested 
chemicals, a brief description of the assay, and the gene symbol, were 
directly downloaded from the ToxCast dashboard (https://comptox.epa. 
gov/dashboard/assay_endpoints/). The assays related to each NR were 
selected using the following gene symbols: progesterone receptors 
(PGR), estrogen receptors α and β (ESR1 and ESR2), aryl hydrocarbon 
receptor (AHR), androgen receptor (AR), and glucocorticoid receptor 
(NR3C1). The final list of assays from ToxCast/Tox21 programs taken 
into consideration is detailed in Table S2. For each assay, the “Assay 
type” was defined based on the description provided in “Assay function 
type” found in the detailed description of the assay. Assays were 
considered as tests for agonist or antagonist activities when the “Assay 
function type” was either “reporter gene” (TOX21 or ATG assays) or 
“detection of steroid hormones” (CEETOX assays), analyzed for gain of 
activity (agonist test) or for loss of activity (antagonist test). Assays for 
which “Assay function type” was “Binding”, “Signaling” or not provided 
were not accounted in results presented in Table 1 and Table S3. 
Fig. 1. Flowchart describing the procedure followed for searching and collecting in vitro and in silico data. * The paper contains tests for ER, AR, PR, GR, or 
AhR agonist or antagonist activities for the relevant FR. ** The assays were selected using the gene symbols: progesterone receptors (PGR), estrogen receptors α and β 
(ESR1 and ESR2), aryl hydrocarbon receptor (AHR), androgen receptor (AR), and glucocorticoid receptor (NR3C1). # As reported in the source. $ For anti- 
androgenic activity. 
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However, these results are provided in Table S1 and are commented in 
the text as complementary information to results from agonist and 
antagonist assays, when relevant. 
2.4. Computational and in silico predictive models 
Information from computational and in silico models predicting the 
anti-AR activity or binding affinity of ligands (replacement FRs) with the 
AR was collected either from ToxCast (where results from the “toxcast 
pathway model” and the “Collaborative Modeling Project for Androgen 
Receptor Activity - CoMPARA” model are provided) or using the open- 
source platform Endocrine Disruptome®. The “toxCast pathway 
model” for AR activity is a mathematical AR pathway-based model that 
integrates the results from 11 high-throughput screening in vitro assays 
from the US EPA’s ToxCast and Tox21 data into the network model for 
AR pathway (Kleinstreuer et al., 2017). The result of the model is 
expressed as an area under the curve (AUC) normalized to the positive 
control, hydroxyflutamide, for AR antagonism. CoMPARA is a consensus 
model which is based on in silico methods, such as quantitative struc-
ture–activity relationship (QSAR) and read-across, and predicts the 
binding, agonist, and antagonist AR activities (Mansouri et al., 2020). 
The results are presented as active/inactive binders, agonists, and 
Table 1 
Summary of agonist and antagonist activities of replacement FRs against 5 NRs, as reported in the peer-review literature and ToxCast database.  
Groups: A, all ten activities have been tested, information from several sources; B, information incomplete - not all activities tested and/or only one source (e.g., 
ToxCast); C, no information found for any of the ten activities. 
Ax/INx: number of assays (x) in which the chemical was indicated as active (A) or inactive (IN). 
Heat map: color coding relates to the number of assays in which the chemical was active, and the proportion of active vs. inactive assays: Yellow: (A < 3 AND IN ≥ A) 
OR A = 1 - Weak evidence of activity; Orange: (A ≥ 3 AND IN ≥ A) OR (1 < A ≤ 4 AND IN < A) - Moderate evidence of activity; Red: A > 4 AND IN < A - Strong evidence 
of activity. 
* na - information on tonnage NOT AVAILABLE (not registered in REACH, for example). 
** all five papers from the same laboratory. 
ER, estrogen receptor; AR, androgen receptor; GR, glucocorticoid receptor; PR, progesterone receptor; AhR, Aryl hydrocarbon receptor; NT, not tested. 
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antagonists. Endocrine Disruptome® is an open-source, web-based 
prediction tool that runs on an open-source platform called Docking 
interface for Target Systems (DoTS) and uses molecular docking to 
predict the binding of chemicals to different human NRs (Koľsek et al., 
2014). The input system is the chemical structure that can be drawn, or 
its simplified molecular-input line-entry system (SMILES). Results are 
provided as binding free energies (in kcal mol− 1) and the probability of 
binding represented by color-coding. The binding probability is calcu-
lated from the true positive rate (sensitivity, SE) and the validation ex-
periments presented as red color indicating a high probability of 
binding, (SE < 0.25), orange and yellow representing medium proba-
bility, (0.25 < SE < 0.50) and (0.50 < SE < 0.75) respectively, and green 
representing the low probability of binding (SE > 0.75) (Koľsek et al., 
2014). In the current review, medium to high probability for receptor 
binding was considered as active for AR antagonism. 
3. Results and discussion 
3.1. General observations from available data 
To facilitate the discussion, the 52 replacement FRs were divided 
into three different groups based on data availability for the investigated 
ED activities (see Table 1 and Fig. 2A). For Group A (13 FRs), some 
information was found on their interactions with all ten studied ED 
activities, i.e., agonist- or antagonist effects towards ER, AR, GR, PR, and 
AhR. For Group B (15 FRs), some but incomplete information was found 
(either data were not found for all the activities, or they were found only 
from one source). For Group C (the remaining 24 FRs), no information 
on ED activities towards studied NRs was found. 
Two replacement FRs, TCEP and triethyl phosphate (TEP), appeared 
to be overall inactive towards the studied NRs. For TCEP, this finding, 
however, does not correspond to its reported adverse effects related to 
male fertility in rodents (Chen et al., 2015; US-EPA, 2015). This could be 
explained by interference of TCEP with other receptors or enzymes not 
reviewed here, but it may also indicate a more general inconsistency 
between in vitro and in vivo toxicological data for TCEP. It was already 
noticed in a recent publication that TCEP is mostly inactive in in vitro 
tests, while in vivo data tends to indicate high hazard (Bajard et al., 
2019). This may be related to, e.g., different in vivo bioavailability or 
toxicokinetics that cannot be fully captured by in vitro screens for pri-
oritization of chemicals. Differences between species might also account 
for these inconsistencies since most in vivo assays are performed in ro-
dents or fishes, while in vitro assays often use human cell lines, for 
example. Such inconsistencies between in vitro and in vivo data may exist 
for other chemicals as well and might be missed in case the data are 
insufficient. The example of TCEP highlights the limitation of relying 
exclusively on one or the other type of data to evaluate the hazard of 
substances. 
One general observation was also the inconsistency of data from 
different information sources. Interestingly, different studies that used 
the same assays for testing the same activity might report that the 
chemical was active, while others indicated no activity. In most cases, 
the variability in the results presumably originates from substantial 
differences in the experimental setup, including the type of the in vitro 
assay or cells, the sensitivity of the assay, the time- and concentration 
ranges tested, etc. However, in some cases, this might even reflect the 
differences in the criteria used for classifying a chemical as active or 
inactive. For example, in several research papers, chemicals are 
considered inactive if no effect is detected below a given concentration 
of the chemical (e.g., 10 µM in (Suzuki et al., 2013)). On the other hand, 
in ToxCast, a chemical is considered inactive if none of the three 
regression parameters, which are automatically derived for the obtained 
assay (i.e., constant, hill and gain-loss), sufficiently fits the dos-
e–response curve (Ryan, 2017). For example, regarding the anti-GR 
activity of TDCIPP, two studies reported that the chemical was “inac-
tive” (i.e., not active below 10 µM), which is however consistent with 
four other sources that reported that TDCIPP was “active” with effective 
concentrations ranging from 16 to 132 µM (Table S1). 
Fig. 2. – Summary of in vitro data availability and reported activity of 52 replacement FRs for five NRs. A. Data availability for in vitro tests for the 10 ED 
activities. Percentage of the 52 reviewed replacement FRs in each group A, B, and C. For 46% of the 52 replacement FRs, no data were found, and for 29%, it was 
incomplete. B. Number of replacement FRs from group A and group B reported active (blue) vs. inactive (orange) for each of the ED activities. *Chemical was reported 
active in at least one study. ** Chemical was reported inactive in all the available studies. C. Anti-androgenic activity of Group C replacement FRs predicted from two 
computational models. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
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3.2. Replacement FRs with solid evidence showing a high potential to 
modulate NRs 
Within Group A and Group B FRs, the chemicals that were more 
frequently reported to be active than inactive and that showed activity 
in at least two assays were examined in more detail. We investigated the 
effective concentrations to identify replacement FRs that are likely to 
present the strongest ED potential via NRs. 
For TPhP, there was solid evidence for estrogenic activity supported 
by the results from 11 assays both from ToxCast and from four research 
papers (Table 1, Tables S1 and S3) (Kojima et al., 2016, 2013; Suzuki 
et al., 2013; Zhang et al., 2014). ER agonistic activity for TPhP was 
consistently observed at low effective concentrations ranging from 0.27 
to 10.9 µM, which are below the cytotoxicity limit of 11.7 µM reported in 
ToxCast (Kojima et al., 2016, 2013; Suzuki et al., 2013; Zhang et al., 
2014). Also, TPhP was active in seven additional assays testing for ER 
binding (Table S1). The data collected also revealed that TPhP antago-
nizes the PR. The high anti-PR activity was reported in all the five assays 
tested, with effective concentrations ranging from 1.14 to 19 µM. There 
is also good evidence of antagonist activity against AR for TPhP. It was 
active in six assays, with effective concentrations ranging from 5.8 to 
78.6 µM (Table S1). It was inactive in the other four assays, but for two 
ToxCast assays, it was flagged as “borderline inactive” because it showed 
a clear dose–response (DR) and almost reached the cut-off threshold 
(Figure S1A and B). Some evidence also supports antagonist activity 
against GR: TPhP was active in four assays (effective concentrations 
ranging from 2.6 to 15 µM) and inactive in another eight assays. Overall, 
results show that there is solid in vitro evidence supporting the ED po-
tential of TPhP. This is in line with in vivo animal studies in rodents and 
zebrafish and small epidemiologic studies that reported adverse effects 
on fertility and pregnancy outcomes (Carignan et al., 2017; Chen et al., 
2015; Liu et al., 2013; Meeker et al., 2013; Meeker and Stapleton, 2010; 
US-EPA, 2015). Consistently, TPhP is listed in the UNEP list of (poten-
tial) EDCs, and both the French Agency for Food, Environmental and 
Occupational Health & Safety (ANSES) and the European Chemicals 
Agency (ECHA) noted in their recent reports a potential concern for 
endocrine disruption and a need for additional data (ANSES, 2018; 
ECHA, 2019). TPhP is also in the list of chemicals going through ECHA’s 
ED assessment, although the status is still under development 
(https://echa.europa.eu/fr/ed-assessment). The data collected in this 
review strongly support its classification as an EDC. 
The review also revealed solid evidence of potential in vitro ED ef-
fects of TDCIPP. Anti-androgenic activity (AR antagonist) seems well 
established: eight assays reported activity with effective concentrations 
ranging from 1.9 to 75.5 µM (Table S1). This is further supported by 
activity in four additional ToxCast assays testing for binding to AR or 
assessing AR-dependent cell growth. Anti-androgenic activity and 
binding to AR are also predicted by two models in ToxCast (Table 2). The 
antagonist activity of TDCIPP against PR was reported in two assays 
with an IC50 as low as 0.85 µM (Suzuki et al., 2013), which was further 
supported by activity in two ToxCast assays for binding towards PR 
(Table S1). The collected evidence also points to moderate antagonist 
GR activity GR: activity was reported in four assays (effective concen-
trations from 16 to 132 µM), one ToxCast assay flagged as “borderline 
inactive” (see dose–response (DR) curve in Figure S1C), and two assays 
with no activity below 10 µM (Table S1). Finally, although one study 
reported estrogenic activity with a REC20 of 6.4 µM (Zhang et al., 2014), 
this was not confirmed in any of the remaining 12 assays in which 
TDCIPP was tested for ER-agonist activity, although one of them clas-
sified it as “borderline inactive” in ToxCast (see DR curve in Figure S1D). 
Overall, the data collected here point to anti-androgenic and anti-PR 
activities of TDCIPP in vitro, which is in line with the few in vivo ro-
dent and human studies available (WHO, 1998; Meeker and Stapleton, 
2010; Meeker et al., 2013; US-EPA, 2015; Carignan et al., 2017; see also 
Bajard et al., 2019 for review). Altogether, these data show the ED po-
tential of TDCIPP and call for a thorough assessment. 
Finally, a large amount of data was found for TBBPA. Seven assays 
reported anti-androgenic activity (anti-AR), and two additional assays 
reported binding to AR but with highly variable effective concentrations 
ranging from 0.022 to 91.1 µM. It should also be noted that TBBPA was 
reported inactive in the other seven assays testing for antagonist activ-
ity. Nevertheless, three of these studies set a 10 µM threshold (Hamers 
et al., 2006; Harju et al., 2007; Molina-Molina et al., 2013), and the 
results may still be consistent with other studies reporting effective 
concentrations above this value. The activity of TBBPA was also re-
ported in some assays for ER, GR, and PR, with some effective concen-
trations in the µM range for PR agonist activity, for example. However, 
many assays testing for the same outcome reported inactivity (Table S1). 
Collected evidence indicates some ED potential for TBBPA, but firm 
conclusions regarding ED assessment are hindered by data 
inconsistencies. 
The activities for three additional replacement FRs should also be 
highlighted, although there is currently less evidence. First, 4-(1,2- 
dibromoethyl)-1,2-dibromocyclohexane (DBE-DBCH) seems to be a 
strong AR agonist with low EC50s within the nM range (depending on 
the DBE-DBCH isomer) (Table S1). These low effective concentrations 
were reported in five studies coming from the same research team using 
different reporter assays (Asnake et al., 2014; Khalaf et al., 2009; 
Kharlyngdoh et al., 2016; Larsson et al., 2006; Pradhan et al., 2013). 
This androgenic activity may underly the strong effects of DBE-DBCH on 
gonadal differentiation observed in amphibians at low exposure levels 
(Liu et al., 2017) and deserves further examination and confirmation by 
independent studies. Second, isopropyl triphenyl phosphate (ip-TPP) 
seems to be an ER agonist, and its estrogenicity was reported in three 
ToxCast assays showing low AC50s ranging from 1.71 to 5 µM 
(Table S1). Another ToxCast assay where cell growth is used as an in-
direct reporter for estrogenic activity (ACEA-ER-80hr) also supports the 
estrogenic potential of ip-TPP. These in vitro data support the repro-
ductive and developmental toxicity of ip-TPP previously reported in rats 
and potentially in humans (Carignan et al., 2018; US-EPA, 2015). 
Altogether, this calls for further studies and thorough risk assessment 
because high exposures cannot be excluded as ip-TPP is a component of 
the FM 550 flame retardant mixture and is registered with high tonnage 
use in the EU REACH. Finally, evidence suggests anti-ER activity of 
pentabromophenol (PBP). The chemical was reported to be active in all 
four ToxCast assays in which it was tested, with AC50s ranging from 
6.15 to 67 µM (Table S1). To our knowledge, information on ED effects 
in vivo for this chemical is missing and should be generated. 
3.3. Shared activity profiles of several replacement FRs - antagonist 
activities against AR and PR 
For the 28 FRs from Groups A and B, some similarities in their ED 
profiles were observed (see Table 1 and Fig. 2B). First, the large majority 
of the tested replacement FRs did not display direct agonist activities 
towards AR, GR, and PR, neither antagonist activity against AhR, 
although AhR data was too scarce to draw firm conclusions. Second, 
antagonistic activities towards AR and PR were frequently observed, and 
12 replacement FRs (namely, TDCIPP, TPHP, TMPP, TBBPA, tri(2- 
butoxyethyl) phosphate (TBOEP), tris(1-chloro-2-propyl) phosphate 
(TCIPP), tri-n-butyl phosphate (TNBP), ip-TPP, cresyl diphenyl phos-
phate (CDP), tri-iso-butyl phosphate (TIBP), tribromoneopentyl alcohol 
(TBNPA) and PBP) were reported active at least once for both anti-AR 
and anti-PR. For eight of these FRs, there are also reports of estrogenic 
activity. This generic pattern of shared anti-AR, anti-PR, and estrogenic 
activities was also described by Suzuki and colleagues for TDCIPP, TPhP, 
TMPP, and some PBDEs, using hierarchical clustering (Suzuki et al., 
2013). Seventeen FRs from Groups A and B have also been reported to 
have antiestrogenic activity in at least one assay, but, for 14 of them, 
there are more reports of inactivity, raising some doubts on the anti-
estrogenic effect. Similarly, ten replacement FRs were shown to have 
anti-GR activity in at least one assay, but for seven of them, there are 
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Table 2 
Anti-androgenic properties of replacement FRs: detailed information from in vitro tests and three predictive models.  
Ax/INx: number of assays (x) in which the chemical was indicated as active (A) or inactive (IN). 
Heat map: color coding relates to the number of assays in which the chemical was active, and the proportion of active vs. inactive assays: Yellow: (A < 3 AND IN ≥ A) 
OR A = 1 - Weak evidence of activity; Orange: (A ≥ 3 AND IN ≥ A) OR (1 < A ≤ 4 AND IN < A) - Good evidence of activity; Red: A > 4 AND IN < A - Strong evidence of 
activity. 
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data from more anti-GR assays in which the same compounds were 
found inactive. 
Because the anti-androgenic activity was consistently reported for 
most Group A and B FRs, results of computational and in silico models 
were also examined for all replacement FRs from the list, including the 
27 other FRs for which no in vitro data on anti-androgenic activity was 
found. A QSAR model from the international collaboration CoMPARA 
(Mansouri et al., 2020) predicted AR antagonist activity for 9 of these 27 
compounds with no in vitro data (namely, N,N’-ethylenebis(tetra-
bromophthalimide) (EBTEBPI), hexachlorocyclopentenyldibrom 
ocyclooctane (DBHCTD), decabromodiphenylethane (DBDPE), tris(2,3- 
dibromopropyl)isocyanurate (TDBP-TAZTO), resorcinol bis(diphenyl-
phosphate) (RDBPP), Dechlorane 602 (DDC-DBF), Dechlorane Plus 
(DDC-CO), (1,2-bis(2,4,6-tribromophenoxy)ethane) (BTBPE) and 
pentabromophenoxy-nonabromodiphenyl ether (4′-PeBPO-BDE208)) 
(Table 2 and Fig. 2C). The Endocrine Disruptome model predicted me-
dium probability of binding to the antagonist conformation of the AR for 
15 of these 27 replacement FRs, namely, DBE-DBCH, pentabromoto-
luene (PBT), TDBP-TAZTO, 2-(2-hydroxyethoxy)ethyl 2-hydroxypropyl 
3,4,5,6-tetrabromophthalate (HEEHP-TEBP), BTBPE, DBHCTD, pen-
tabromobenzyl acrylate (PBB-Acr), 2,3,5,6-tetrabromo-p-xylene (TBX), 
hexabromocyclodecane (HBCYD), dibromostyrene (DBS), 1,3-bis(2,3- 
dibromopropyl)-5-(2-propen-1-yl)-1,3,5-triazine-2,4,5(1H,3H,5H)-tri-
one (BDBP-TAZTO), 1-(2,3-dibromopropyl)-3,5-diallyl-1,3,5-triazine- 
2,4,6(1H,3H,5H)-trione (DBP-TAZTO), 2,4-dibromophenol (DBP), 
Dechlorane 604 (HCTBPH/Dec 604), and diethylphosphinic acid 
(Table 2 and Fig. 2C). For six compounds, no prediction was obtained 
because the platform does not support the docking of ligands with mo-
lecular weights exceeding 600 g/mol. The in silico predicted binding of 
replacement FRs to anti-AR is presented in Table 2, where the affinity is 
represented by color coding based on the probability of binding with the 
receptor from higher to lower order; red > orange > yellow > green. The 
results are consistent with the conclusion reached by Wang and col-
leagues in a recent study using a computational tool to predict the 
binding affinity of 25 organophosphate esters (of which several were 
replacement FRs) with 12 NRs (Wang et al., 2020). The authors also 
validated the accuracy of Endocrine Disruptome tools by comparing the 
predictions with experimental data from the literature and observed that 
the predictions were relatively reliable with an accuracy, sensitivity, and 
specificity of 78.8, 60.0, and 80.9%, respectively. The ToxCast pathway 
model could not predict activity for these chemicals as it works/or in-
tegrates data from the already existing ToxCast/TOX21 research pro-
gram where these chemicals have not been tested yet. Considering the 
anti-AR activity predicted by the in silico models (CoMPARA or Endo-
crine Disruptome), 21 replacement FRs may therefore be added to the 19 
FRs from Group A and B that showed anti-AR activity in one or more 
assays. Further evaluation is needed for the compounds for which no 
predictions were obtained in either of the models due to certain limi-
tations (for instance, tris(tribromoneopentyl)phosphate (TTBNPP), 
2,4,6-tris(2,4,6-tribromophenoxy)-1,3,5-triazine (TTBP-TAZ) and 
octabromotrimethyphenyl indane (OBTMPI)). 
Overall, these shared toxicological profiles highlight the possibility 
of additive or synergic ED-like effects (anti-androgenic in particular) 
among these replacement FRs. Such mixture effects may increase the 
toxicological potency of individual chemicals when acting in mixtures, 
as shown, for example, in male reproductive tracts of rats exposed to a 
mixture of 18 anti-androgenic compounds (Conley et al., 2018). Mixture 
effects of replacement FRs are of real concern, considering repeatedly 
reported co-occurrence of replacement FRs in dust, fish, wildlife, and 
human samples (Demirtepe et al., 2019; Malarvannan et al., 2015; Mitro 
et al., 2016; Saillenfait et al., 2018; Shi et al., 2016; Sundkvist et al., 
2010). 
3.4. Critical gaps in knowledge 
For 24 out of the 52 replacement FRs screened, no experimental in 
vitro data related to interactions with the selected NRs were found. For 
several of these Group C FRs, there are indications of broad use, and 
human exposure is thus likely. Five out of these Group C FRs (DBDPE, 
DDC-CO, TTBNPP, bisphenol A bis(diphenylphosphate) (BPA-BDPP) 
and EBTEBPI) are registered in the EU REACH legislation with high or 
very high tonnage (up to the 10,000–100,000 tonnes per year for 
DBDPE). Many of these Group C FRs have been detected in indoor dust 
or air, such as DBDPE, DDC-CO, Dechlorane 603 (DDC-Ant), TTBP-TAZ, 
BTBPE, BPA-BDPP, DBHCTD, RBDPP, and PBB-Acr (Ballesteros-Gömez 
et al., 2014; Brandsma et al., 2013; Demirtepe et al., 2019; Guo et al., 
2018a; Khairy and Lohmann, 2018; Kurt-Karakus et al., 2017; Li et al., 
2015; Nguyen et al., 2019; Rantakokko et al., 2019; Vojta et al., 2017), 
or in human matrices, such as BTBPE, DBDPE, DBHCTD, DBP, DDC-Ant, 
DDC-CO, DDC-DBF/Dechlorane 602, OBTMPI, and TBX (Čechová et al., 
2017; Fromme et al., 2015; Haglund et al., 2016; Shi et al., 2016; Zhou 
et al., 2014b, 2014a). Therefore, generating comprehensive toxicolog-
ical data for these compounds should be a research priority. 
For some of the 15 replacement FRs included in Group B (i.e., only 
scarce experimental data available), low effective concentrations below 
10 µM have been reported, which may indicate a higher toxicological 
concern. These include, for example, estrogenic activity (for ip-TPP and 
CDP), anti-estrogenic activity (for PBP), anti-androgenic activity (for 2- 
ethylhexyl-2,3,4,5-tetrabromobenzoate (EH-TBB)), agonist activity to-
wards PR (for HBB), androgenic activity (for HBB and DBE-DBCH, also 
known TBECH), and agonist AhR activity (for and 2,2-bis(chloromethyl) 
trimethylenebis[bis(2-chloroethyl) phosphate] (V6)) (Table 1 and 
Table S1). Further studies are needed to confirm these preliminary ob-
servations, especially for compounds like ip-TPP, which is registered 
under EU REACH with high tonnage, for EH-TBB, used in commercial FR 
mixtures FM550 and FM BZ54, and often detected in home dust (Dem-
irtepe et al., 2019; Nguyen et al., 2019; Stapleton et al., 2014; Yang 
et al., 2020), or for V6 which was detected in baby products and dust 
(Fang et al., 2013). 
It also appears that, in general, limited AhR data were available for 
the 52 replacement FRs screened, although this is an important mediator 
of various chronic toxicities, such as immunotoxicity, developmental 
and reproductive toxicity (Petersen et al., 2006; Rothhammer and 
Quintana, 2019). Indeed, agonist and antagonist AhR data were only 
available for 23 and 18 replacement FRs, respectively, and came almost 
exclusively from ToxCast. The exceptions were three studies with 2,4,6- 
tribromophenol (246-TBP), TBBPA, HBB, and/or PBT, of which one 
showed AhR-agonist activity for HBB and PBT (Brown et al., 2004; 
Hamers et al., 2006; Harju et al., 2007), and one study reporting AhR- 
agonist activity at relatively low effective concentrations for eight out 
of nine replacement FRs included in our initial list (Rosenmai et al., 
2021). As shown in Table 1, the majority of the tested replacement FRs 
were inactive for AhR-antagonist activity in this limited set of tests (16 
out of 18). 
In summary, for the 39 replacement FRs included in Groups B and C 
(limited or no information was available on the activities associated 
with the studied NRs), priority should be given to those produced in the 
highest amounts and/or which have been detected at significant levels 
* na - information on tonnage NOT AVAILABLE (not registered in REACH, for example) # Antagonist/Binding. 
For the Endocrine disruptome tool: The binding probability is represented with the following color coding; red color indicates a high probability of binding (SE < 0.25), 
orange and yellow represent medium probability, (0.25 < SE < 0.50) and (0.50 < SE < 0.75) respectively, and green represent the low probability of binding (SE >
0.75) to anti-AR. ** Dark grey indicates chemicals for which the models fail to predict due to high molecular weight (>600 g/mol). 
## https://pubs.acs.org/doi/10.1021/acs.chemrestox.6b00347 - ≥ 0.1 = Active ; 0.1 > x ≥ 0.001 = very weak, considered inconclusive ; < 0.001 = inactive. 
ER, estrogen receptor; AR, androgen receptor; GR, glucocorticoid receptor; PR, progesterone receptor; AhR, Aryl hydrocarbon receptor; NT, not tested.. 
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in the environment or human matrices, such as DBDPE, DDC-CO or V6 
(Fang et al., 2013; Stapleton et al., 2011). In addition, a recent human 
study has reported significant statistical associations between levels of 
EH-TBB, BTBPE, DBE-DBCH, DDC-CO, or DBDPE and the sex steroids 
follicle-stimulating hormone (FSH) and/or testosterone in blood sam-
ples from local residents of an e-waste dismantling region in China (Guo 
et al., 2018b). These replacement FRs may have ED potential, and more 
tests on these ED properties and additional biomonitoring exposure data 
in human populations are needed. 
3.5. Other ED activities 
This review focuses on in vitro and in silico data related to interactions 
with 5 NRs, which represent a subset of potential targets of EDCs. 
Indeed, receptor agonism and antagonism examined in this review 
constitute two of the ten key characteristics of EDCs defined in an expert 
consensus statement, which include, for example, signal transduction, 
hormone synthesis, or hormone transport (La Merrill et al., 2020). Other 
ED properties of replacement FRs may not be fully reflected. For 
example, TPhP showed activity in an enzyme-based assay in a high 
throughput screening for EDCs (Morisseau et al., 2009). Another 
frequent target of EDCs is the thyroid hormone pathway/homeostasis, 
and some replacement FRs were reported to interfere with it. For 
instance, PBP, 246-TBP or TBBPA are very potent competitive inhibitors 
of the thyroxine (T4) binding to transthyretin (TTR) in vitro (Hamers 
et al., 2006; Meerts et al., 2000), and TNBP, TMPP, TDCIPP, and TCIPP 
were reported to inhibit the binding of the triiodothyronine (T3) hor-
mone to thyroid receptor β (Zhang et al., 2016). In vitro interactions with 
TTR were also reported for a few more replacement FRs, with two 
studies describing either an increase in T4-TTR binding after exposure to 
TPhP, TDCIPP, TEP, and TBOEP (Hill et al., 2018), or a TTR displace-
ment induced by TPhP, CDP, TMPP and EHDPP (Rosenmai et al., 2021). 
Besides, several lines of evidence also link TDCIPP and TPhP to the 
thyroid hormone pathway in humans and fishes. Both compounds were 
shown to affect thyroid hormone levels (Kim et al., 2015; Meeker et al., 
2013; Meeker and Stapleton, 2010; Preston et al., 2017; Wang et al., 
2015), and some adverse effects that may result from thyroid disruption, 
such as neurodevelopmental defects (Castorina et al., 2017; Jarema 
et al., 2015; Lipscomb et al., 2017; Noyes et al., 2015). Exposure to TPhP 
may also be associated with increased risks of papillary thyroid cancer in 
humans (Hoffman et al., 2017b). These other aspects of ED add to the 
evidence collected in this paper as arguments for classifying TPhP, 
TDCIPP, and possibly TBBPA and PBP as potential EDCs, and would 
deserve deeper and more systematic analysis. In agreement with these 
conclusions, all four are in the list of potential endocrine disruptors 
elaborated by the endocrine disruption exchange (TEDX, Search the 
TEDX List — The Endocrine Disruption Exchange). 
4. Conclusions 
This comprehensive data mining and its structured presentation (1) 
allowed to assess the consistency of data and identified replacement FRs 
with ED potential, (2) revealed that number of replacement FRs share 
similar profiles of activities against NRs, raising concerns regarding 
possible mixture effects, and (3) highlighted the striking lack of exper-
imental in vitro data for 24 of the 52 studied replacement FRs, including 
high tonnage chemicals or compounds frequently detected in human 
biomonitoring studies. 
The collection of results from in vitro tests on agonist and antagonist 
activities toward five NRs (ER, AR, GR, PR, and AhR) highlighted the ED 
potential of several replacement FRs. It particularly points to TPhP and 
TDCIPP as probable EDCs: estrogenic and anti-PR activity of TPhP, and 
anti-androgenic activity of both TPhP and TDCIPP have repeatedly been 
reported in different assays at relatively low concentrations. This is 
further supported by observations of other ED activities, such as 
disruption of the thyroid hormone pathway. For three other compounds, 
less information was available, but it consistently showed anti- 
estrogenicity (PBP), estrogenicity (ip-TPP), and androgenicity (DBE- 
DBCH). These observations are also supported by a few in vivo studies for 
ip-TPP and DBE-DBCH. TBBPA and TMPP are other replacement FRs 
that were reported active in some assays for estrogenicity, anti- 
estrogenicity, or anti-androgenicity, but because of other conflicting 
data, firm conclusions cannot be drawn. Although this systematic review 
constitutes a point of departure for the identification and prioritization 
of replacement flame retardants with endocrine disruption potential, it 
should be kept in mind that endocrine disruption goes beyond the re-
ceptor level, including other key characteristics (La Merrill et al., 2020) 
that remain to be characterized. 
This work also reveals that tests for activity on these five key NRs are 
critically lacking for 24 replacement FRs, and testing is incomplete for 
the other 15 compounds. Among these 39 replacement FRs, several are 
ubiquitous, and there is a concern for widespread human exposure, 
considering their high production volume and/or confirmed human 
exposure, such as for DBDPE or DDC-CO. 
Finally, the data collected suggest that many replacement FRs might 
share profiles of their ED activities, where 12 replacement FRs were 
reported to be active in both anti-AR and anti-PR assays, of which eight 
also showed estrogenicity. In particular, the anti-androgenic potential is 
of concern and has also been predicted by in silico model(s) for 21 
additional replacement FRs with no in vitro data available. This raises 
high concerns for mixture effects and urges investigation of the ED ac-
tivities of the “non-tested” replacement FRs. Specifically, their anti- 
androgenic potential should be addressed as a priority. 
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